Krystal Biotech, Inc. (KRYS) is a Biotechnology company in the Healthcare sector, currently trading at $270.00. It has a SharesGrow Score of 85/100, indicating a strong investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of KRYS = $949.71 (+251.7% from the current price, the stock appears undervalued). Analyst consensus target is KRYS = $311 (+15.2% upside).
Valuation: KRYS trades at a trailing Price-to-Earnings (P/E) of 36.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.22.
Financials: revenue is $389M, +253.5%/yr average growth. Net income is $205M, growing at +317.7%/yr. Net profit margin is 52.6% (strong). Gross margin is 92.6% (-1.3 pp trend).
Balance sheet: total debt is $9M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 9.95 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $1.3B.
Analyst outlook: 17 / 17 analysts rate KRYS as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 57/100 (Partial), Growth 100/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 66/100 (Partial), Future 94/100 (Pass), Income 100/100 (Pass).
